ZXP-1302

ZXP-1302 is an investigational antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2), developed by Shenzhen Zhenxing Pharmaceutical Technology for the treatment of solid tumors. The drug is specifically designed to address cancers that overexpress CLDN18.2, such as gastric, gastroesophageal junction, and pancreatic cancers. ZXP-1302 consists of a monoclonal antibody specific to CLDN18.2 conjugated to a cytotoxic payload, typically a topoisomerase I inhibitor (such as a camptothecin derivative), via a linker. This targeted approach allows for the selective delivery of the cytotoxic agent to tumor cells, aiming to maximize anti-tumor efficacy while minimizing systemic toxicity. The program is part of Shenzhen Zhenxing's pipeline of next-generation ADCs utilizing site-specific conjugation technologies.